Study confirms performance of new defibrillator with no heart leads

May 19, 2010
Study confirms performance of new defibrillator with no heart leads
Dr. Burke, assistant professor of medicine, holds the new defibrillator.

( -- Results from clinical trials performed in Europe and New Zealand, published online in the New England Journal of Medicine, demonstrate the effectiveness of a new less-invasive, subcutaneous implantable cardioverter defibrillator (ICD) for sudden cardiac arrest, a potentially fatal electrical malfunction of the heart.

The subcutaneous ICD replaces the leads that extend into the heart with sensors and a shock-delivery device placed just beneath the skin over the sternum.

Four studies conducted at eight sites in Europe found that the S-ICD detected 100 percent of induced and spontaneous irregular with 98 percent conversion success. They confirmed that the leadless defibrillator helped reduce problems associated with traditional models, including difficulty implanting the leads, risk of damage to the heart or the device, chance of infection and the need to remove a defective or damaged in or on the heart.

The device received European approval in 2009 and is commercially available there. The publication represents nine years of development and clinical work with 17 medical centers in seven countries. The first U.S. recipient of the device had it implanted March 3, 2010 at the University of Chicago Medical Center.

"The studies show that the S-ICD is ideal for relatively young, healthy patients at high risk of , but who don't need a ," said Martin Burke, DO, director of the Heart Rhythm Center at University of Chicago Medical Center.

While the added distance from the heart means a more powerful shock is delivered by the S-ICD (about 2.5 times stronger than traditional ICDs), the power is still well within a safe range, Burke said. And patients should experience fewer of those shocks, thanks to an improved monitor system that measures more complex heart rhythm characteristics to separate out dangerous cardiac events from false positives.

If an infection related to the device should occur, it would be less dangerous in that location. Removing the device, if necessary, would be much simpler with no cardiac leads.

The researchers plan to enroll up to 330 subjects in a new, larger trial underway at about 35 sites globally, including Chicago, Los Angeles and Atlanta. In the Chicago area, the device is currently available only at the University of Chicago Medical Center.

The first U.S. patient to receive the device was Brooke Bergeron, 38, who was 37 weeks pregnant when she suffered a heart attack, a rare complication of her fourth pregnancy. After the child was delivered via caesarian section and the mother underwent an emergency double-bypass operation, Bergeron's doctors recommended an implantable defibrillator.

Because of her young age, normal heart rate and high risk of cardiac arrest, Bergeron was an ideal candidate for a device without leads, which can be damaged over time.

"Cameron Health's goal in developing the S-ICD System was to significantly improve upon current ICD therapy by reducing the complications associated with transvenous leads, as well as to simplify implantation, programming and follow-up," said Kevin Hykes, President and Chief Executive Officer, Cameron Health, Inc.

"The publication of these data is a clear acknowledgement of the important pioneering contributions made by the clinical investigators. We believe that the S-ICD System has the capability to significantly lower adoption barriers, increase patient acceptance and ultimately save more lives."

Explore further: Recombinant peptide for transplantation of pancreatic islets in mice models of diabetes

add to favorites email to friend print save as pdf

Related Stories

New therapy found to prevent heart failure

Jun 23, 2009

A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) ...

Largest study to date finds benefits of ICDs in children

May 01, 2008

More and more children with congenital heart disease are receiving implantable cardioverter-defibrillators (ICDs) to maintain proper heart rhythm. ICDs were first introduced for adults in the 1980s, but little is known about ...

New Therapy that Prevents Heart Failure (w/ Video)

Sep 01, 2009

( -- Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients ...

Defibrillators save lives, don't diminish quality of life

Sep 04, 2008

Implantable cardioverter-defibrillators (ICDs) reduce the risk of death from sudden cardiac arrest (SCA) among patients with heart failure, and they do so without significantly altering a person's quality of life, say researchers ...

Recommended for you

Novel nanoparticle therapy promotes wound healing

23 hours ago

An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.